Cargando…

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

OBJECTIVE: Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions. Oxyntomodulin is a gut peptide that activates the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Tina, Thomas, Leo, Baader-Pagler, Tamara, Haebel, Peter, Simon, Eric, Reindl, Wolfgang, Bajrami, Besnik, Rist, Wolfgang, Uphues, Ingo, Drucker, Daniel J., Klein, Holger, Santhanam, Rakesh, Hamprecht, Dieter, Neubauer, Heike, Augustin, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679702/
https://www.ncbi.nlm.nih.gov/pubmed/36356832
http://dx.doi.org/10.1016/j.molmet.2022.101633
_version_ 1784834254656503808
author Zimmermann, Tina
Thomas, Leo
Baader-Pagler, Tamara
Haebel, Peter
Simon, Eric
Reindl, Wolfgang
Bajrami, Besnik
Rist, Wolfgang
Uphues, Ingo
Drucker, Daniel J.
Klein, Holger
Santhanam, Rakesh
Hamprecht, Dieter
Neubauer, Heike
Augustin, Robert
author_facet Zimmermann, Tina
Thomas, Leo
Baader-Pagler, Tamara
Haebel, Peter
Simon, Eric
Reindl, Wolfgang
Bajrami, Besnik
Rist, Wolfgang
Uphues, Ingo
Drucker, Daniel J.
Klein, Holger
Santhanam, Rakesh
Hamprecht, Dieter
Neubauer, Heike
Augustin, Robert
author_sort Zimmermann, Tina
collection PubMed
description OBJECTIVE: Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions. Oxyntomodulin is a gut peptide that activates the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) and reduces bodyweight by increasing energy expenditure and reducing energy intake in humans. Here we describe the pharmacological profile of the novel glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) dual agonist BI 456906. METHODS: BI 456906 was characterized using cell-based in vitro assays to determine functional agonism. In vivo pharmacological studies were performed using acute and subchronic dosing regimens to demonstrate target engagement for the GCGR and GLP-1R, and weight lowering efficacy. RESULTS: BI 456906 is a potent, acylated peptide containing a C18 fatty acid as a half-life extending principle to support once-weekly dosing in humans. Pharmacological doses of BI 456906 provided greater bodyweight reductions in mice compared with maximally effective doses of the GLP-1R agonist semaglutide. BI 456906’s superior efficacy is the consequence of increased energy expenditure and reduced food intake. Engagement of both receptors in vivo was demonstrated via glucose tolerance, food intake, and gastric emptying tests for the GLP-1R, and liver nicotinamide N-methyltransferase mRNA expression and circulating biomarkers (amino acids, fibroblast growth factor-21) for the GCGR. The dual activity of BI 456906 at the GLP-1R and GCGR was supported using GLP-1R knockout and transgenic reporter mice, and an ex vivo bioactivity assay. CONCLUSIONS: BI 456906 is a potent GCGR/GLP-1R dual agonist with robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
format Online
Article
Text
id pubmed-9679702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96797022022-11-23 BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Zimmermann, Tina Thomas, Leo Baader-Pagler, Tamara Haebel, Peter Simon, Eric Reindl, Wolfgang Bajrami, Besnik Rist, Wolfgang Uphues, Ingo Drucker, Daniel J. Klein, Holger Santhanam, Rakesh Hamprecht, Dieter Neubauer, Heike Augustin, Robert Mol Metab Original Article OBJECTIVE: Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions. Oxyntomodulin is a gut peptide that activates the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) and reduces bodyweight by increasing energy expenditure and reducing energy intake in humans. Here we describe the pharmacological profile of the novel glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) dual agonist BI 456906. METHODS: BI 456906 was characterized using cell-based in vitro assays to determine functional agonism. In vivo pharmacological studies were performed using acute and subchronic dosing regimens to demonstrate target engagement for the GCGR and GLP-1R, and weight lowering efficacy. RESULTS: BI 456906 is a potent, acylated peptide containing a C18 fatty acid as a half-life extending principle to support once-weekly dosing in humans. Pharmacological doses of BI 456906 provided greater bodyweight reductions in mice compared with maximally effective doses of the GLP-1R agonist semaglutide. BI 456906’s superior efficacy is the consequence of increased energy expenditure and reduced food intake. Engagement of both receptors in vivo was demonstrated via glucose tolerance, food intake, and gastric emptying tests for the GLP-1R, and liver nicotinamide N-methyltransferase mRNA expression and circulating biomarkers (amino acids, fibroblast growth factor-21) for the GCGR. The dual activity of BI 456906 at the GLP-1R and GCGR was supported using GLP-1R knockout and transgenic reporter mice, and an ex vivo bioactivity assay. CONCLUSIONS: BI 456906 is a potent GCGR/GLP-1R dual agonist with robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake. Elsevier 2022-11-07 /pmc/articles/PMC9679702/ /pubmed/36356832 http://dx.doi.org/10.1016/j.molmet.2022.101633 Text en © 2022 Boehringer Ingelheim Pharma GmbH & CoKG https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Zimmermann, Tina
Thomas, Leo
Baader-Pagler, Tamara
Haebel, Peter
Simon, Eric
Reindl, Wolfgang
Bajrami, Besnik
Rist, Wolfgang
Uphues, Ingo
Drucker, Daniel J.
Klein, Holger
Santhanam, Rakesh
Hamprecht, Dieter
Neubauer, Heike
Augustin, Robert
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
title BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
title_full BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
title_fullStr BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
title_full_unstemmed BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
title_short BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
title_sort bi 456906: discovery and preclinical pharmacology of a novel gcgr/glp-1r dual agonist with robust anti-obesity efficacy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679702/
https://www.ncbi.nlm.nih.gov/pubmed/36356832
http://dx.doi.org/10.1016/j.molmet.2022.101633
work_keys_str_mv AT zimmermanntina bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT thomasleo bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT baaderpaglertamara bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT haebelpeter bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT simoneric bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT reindlwolfgang bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT bajramibesnik bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT ristwolfgang bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT uphuesingo bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT druckerdanielj bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT kleinholger bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT santhanamrakesh bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT hamprechtdieter bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT neubauerheike bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy
AT augustinrobert bi456906discoveryandpreclinicalpharmacologyofanovelgcgrglp1rdualagonistwithrobustantiobesityefficacy